Trial Profile
A phase I study assessing Ampligen along with check point inhibitors for pancreatic cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2021
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 26 Feb 2021 New trial record
- 24 Feb 2021 According to a AIM ImmunoTechs media release, this study will be conducted at Erasmus Medical Center.